YPYaojin Peng

Yaojin Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaojin Peng has a total of 473 co-authors. Here are the top co-authors by number of shared publications:

  • Jianwei Lv

    School of Life Sciences Xiamen University Xiamen China

    8 shared publications
  • Tongbiao Zhao

    Standard Committee, Chinese Society for Cell Biology Shanghai China

    7 shared publications
  • Jiani Cao

    State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences Beijing China

    6 shared publications
  • Lei Wang

    State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences Beijing China

    5 shared publications
  • Qi Zhou

    State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

    5 shared publications
  • Zhenyu Xiao

    School of Life Science, Beijing Institute of Technology, Beijing, China

    5 shared publications

Latest Publications

  • China rewrites its regulatory framework for stem cell clinical translation

    by Ruohan Feng, Xue Pang, Yi Hao, Tong Zhao, Yaojin Peng

  • Open Access

    Emerging trends in responsible research and innovation: how China is shaping its life and health data governance ecosystem

    by Ruohan Feng, Yaojin Peng

    The twenty-first century has witnessed an unprecedented convergence of technological advancements in biotechnology, artificial intelligence (AI), and big data analytics, fundamentally reshaping the...

  • Open Access

    Human stem cell-based embryo models: innovation, ethics, and policy

    by Alfonso Martinez Arias, Nicolas Rivron, Shahragim Tajbakhsh, Josephine Johnston, Cantas Alev, Laure Bally-Cuif, Elvan Böke, Tommaso Cavazza, Emma Cave, David Cyranoski, et al.

    The aim of this White Paper is to establish a foundational framework for research, technological development, and regulation in the emerging field of stem cell-based embryo models (SCBEMs). These models, generated from Pluripotent Stem Cells, are designed to recapitulate essential events in early stages of human development. They have the potential to illuminate the early stages of embryo development and implantation and hold promise as an avenue to address global health challenges, including infertility and pregnancy loss, congenital, neonatal and adult conditions, and the need for organ transplants. While SCBEMs are not a substitute for human embryos, their tractability for large-scale analysis and their abilities to model the earliest stages of embryonic development suggest that they will have a significant impact on reproductive biology and regenerative medicine. But SCBEMs do not just raise novel scientific questions; they pose ethical and legal questions that need to be addressed. The paper stems from a meeting of a core group of researchers that met at the Institut Pasteur in Paris in November 2024 and represents the views of an extended group that has worked to elaborate the documents as a consensus for the field. Here, we provide a framework to guide research in this new field. We do this by summarizing the state of the science, assessing current SCBEM research in relation to its primary future applications and addressing the need for continued ethical and regulatory oversight associated with this new field.


  • Optimizing translational efficiency in stem cell clinical research

    by Yi Hao, Qianwen Chen, Jiayu Yin, Lulu Ding, Xue Pang, Yaojin Peng


  • Challenges and Prospects for Cell Therapy Regulation in China

    by Ruohan Feng, Jiayu Yin, Yaojin Peng

    The development of advanced cell-based intervention in China has been rapid, yet it faces a multitude of regulatory challenges. This article comprehensively analyzes the current state and developmental trajectory of the regulatory framework for advanced cell-based intervention in China. The regulation of stem cells and other cell-based interventions in China has undergone multi-phase development, resulting in a relatively well-established regulatory framework that emphasizes pre-clinical research, Good Manufacturing Practices (GMP), and stringent review processes. However, the jurisdiction still confronts several challenges in advanced cell-based intervention regulation. To address these challenges, future regulatory directions in China may include clarifying the drug status of advanced cell-based intervention products, improving technical evaluation systems, establishing risk classification and tiered management systems, strengthening ethical review mechanisms, enhancing the standardization of clinical research, optimizing industrial chain links, and establishing knowledge-sharing platforms.

  • Open Access

    Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

    by Qianwen Chen, Jianwei Lv, Xinwei Xie, Hanlin Zhu, Zhenyu Xiao, Yaojin Peng

    Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy. However, this technique is associated with certain ethical, safety, and regulatory challenges, including ensuring genomic stability, preventing contamination and adhering to rigorous ethical standards for cell sourcing and obtaining informed consent. Addressing these challenges would require robust quality control, transparent data‐sharing practices, and cross‐border collaboration to ensure alignment with ethical and scientific standards. Future development must therefore focus on patient safety, data privacy and equitable access within a comprehensive ethical framework. These measures are crucial for maintaining public trust in and enabling the responsible clinical integration of PSC‐NK therapies, thereby supporting their advancement while maintaining a balance between innovation and societal and ethical considerations.


  • The X-Age Project to construct a Chinese aging clock

    by Jiaming Li, Mengmeng Jiang, Qiaoran Wang, Zikai Zheng, Jianghua Shen, Jingyi Li, Muzhao Xiong, Yandong Zheng, Xiaoyong Lu, Yusheng Cai, et al.

    The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.


  • Governance of cross-border genomic data sharing through a human rights approach

    by Liang Yu, Ruohan Feng, Youhai Sun, Yaojin Peng

    Cross-border genomic data sharing is crucial for advancing research progress, understanding of genetic diversity and international public health. However, this practice also leads to concerns regarding biosecurity, individual privacy and regulatory conflicts. Scientific communities often advocate data sovereignty approaches to address these challenges, yet related frameworks are often inadequate in their ability to address such challenges and have an overemphasis on national control and protectionism. They also may not fully consider the inherently transnational nature of genomic data and the need for a governance system that reflects the shared human heritage of the data and global interconnectivity. Instead, we propose here a human rights-based approach that surpasses territorial boundaries to promote shared responsibility and equitable research practices. A balanced governance framework that incorporates extraterritorial obligations and aligns data policy with human rights principles can safeguard individual privacy and biosecurity, encourage international collaboration and support ethically responsible genomic research.


  • Ethical concerns in aging research: perspectives of global frontline researchers

    by Yaojin Peng, Lulu Ding, Zhenyu Xiao, Moshi Song, Jianwei Lv, Guang-Hui Liu

    This study investigated the ethical landscape of aging research amid the increasing global focus on extending the human lifespan and health span. Our global survey of 180 researchers across 38 jurisdictions revealed divergent perceptions of aging, a consensus regarding the feasibility of delaying aging, and multiple perspectives regarding lifespan extension. The present findings underscore a paradigm shift toward inclusive and ethically sound research, emphasizing the need for an approach that strikes a balance between basic and clinical research. In addition, this study highlighted key ethical concerns in aging research, including the effects of misleading advertising, potential inequality in access to aging interventions, and risks pertaining to the extrapolation of research findings from lower-model organisms to humans. The insights presented in this paper call for an integrated approach for overcoming the complex ethical and societal challenges in aging research to ensure responsible and equitable advancements in this burgeoning field.


  • Open Access

    Technical specifications for ethics review of human stem cell research

    by Yaojin Peng, Aijin Ma, Zhenyu Xiao, Jie Hao, Ruohan Feng, Changlin Wang, Baoyang Hu, Peijun Zhai, Ka Li, Lei Wang, et al.

    The rapid advancement of human stem cell research and its expansion into emerging areas has resulted in an escalation of ethical challenges associated with these studies. As a result, there has been a corresponding increase in both the volume and complexity of institutional ethics reviews, coupled with higher expectations for the quality of the review process. In response to these challenges, this standard provides a comprehensive outline of the fundamental principles, content, types, and procedures of ethics review, specifically focusing on non‐clinical human stem cell research. Its purpose is to provide clear operational and procedural guidelines, as well as recommendations, for the ethics review of such studies. The document was originally published by the Chinese Society for Cell Biology on August 30, 2022. It is our hope that the publication of these guidelines will facilitate the integration of ethical considerations and evaluations in a structured manner throughout the entire process of stem cell research, ultimately fostering a healthy and orderly development of the field.